目的 探讨L3骨骼肌指数(L3SMI)在胰腺炎病程进展中的应用价值。方法 选择2020-08至2023-08武警广东总队医院就诊的146例胰腺炎患者,选择同期79名健康体检者作为对照组。所有参与者均进行CT检查测定L3SMI。采用酶联免疫吸附实验测量血清中白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、C-C趋化因子配体2(CCL2)和瘦素水平并建立四元线性回归模型,以排除可能的混杂因素。结果 在调整模型后,L3SMI指数在对照组,首次胰腺炎(FAP)组患者、复发性急性胰腺炎(RAP)患者以及慢性胰腺炎(CP)组患者中呈显著降低趋势(P趋势分别为0.005、0.019和0.020)。在所有模型中,瘦素与L3SMI显著负相关(模型1:β=-0.005,P=0.021;模型2:β=-0.004,P=0.044;模型3:β=-0.003,P=0.063;模型4:β=-0.004,P=0.054),其他因子与L3SMI无显著相关性。结论 L3SMI在从FAP到RAP再到CP的连续过程中逐渐减少,瘦素的变化水平可能是其中的一个重要影响因素。
Abstract
Objective To investigate the application value of L3 skeletal muscle index (L3SMI) in the progression of pancreatitis. Methods A total of 146 patients with pancreatitis and 143 healthy people from August 2020 to August 2023 at Guangdong Provincial Corps Hospital of Chinese People's Armed Police Force were included in this study. All participants underwent CT examination to determine L3SMI. Serum levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), C-C chemokine ligand 2 (CCL2) and leptin were measured by enzyme-linked immunosorbent assay(ELISA), and a four-element linear regression model was established to exclude possible confounding factors. Results After adjusting the model, the L3SMI index showed a significant decreasing trend in the control group, first-time pancreatitis(FAP) group, recurrent acute pancreatitis(RAP) group, and chronic pancreatitis(CP) group (p-trends of 0.005, 0.019, and 0.020, respectively). Leptin was significantly negatively correlated with L3SMI in all models (Model 1: β=-0.005, P=0.021; Model 2: β=-0.004,P=0.044; Model 3: β=-0.003, P=0.063; Model4: β=-0.004, P=0.054). There was no significant correlation between other factors and L3SMI. Conclusions L3SMI decreases gradually during the continuous process from FAP to RAP and CP, and the changes of leptin level may be an important influencing factor.
关键词
L3骨骼肌指数 /
胰腺炎 /
瘦素
Key words
L3 skeletal muscle index /
pancreatitis /
leptin
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Xiao A Y, Tan M L, Wu LM, et al. Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis and meta-regression of population-based cohort studies[J]. Lancet Gastroenterol Hepatol, 2016,1(1):45-55.
[2] Pendharkar S A, Mathew J, Petrov M S. Age- and sex-specific prevalence of diabetes associated with diseases of the exocrine pancreas: a population-based study[J]. Dig Liver Dis, 2017, 49(5): 540-544.
[3] Guda N M, Muddana V, Whitcomb D C, et al. Recurrent acute pancreatitis: international state-of-the-science conference with recommendations[J]. Pancreas 2018,47(6):653-666.
[4] Sankaran S, Xiao A, Wu L, et al. Frequency of progression from acute to chronic pancreatitis and risk factors: a meta-analysis[J]. Gastroenterology, 2015,149(6):1490-1500.
[5] Cho J, Scragg R, Pandol S J, et al. Antidiabetic medications and mortality risk in individuals with pancreatic cancer-related diabetes and postpancreatitis diabetes: a nationwide cohort study[J]. Diabetes Care, 2019,42(9):1675-1683.
[6] 石志文, 李 娟, 曾 欣,等. L3骨骼肌指数在疾病预后评估中的应用[J]. 第二军医大学学报, 2019, 40(4):420-425.
[7] Fedorov A, Beichel R, Kalpathy-Cramer J, et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network[J]. Magn Reson Imaging, 2012,30(9):1323-1341.
[8] DeSouza S V, Priya S, Cho J, et al. Pancreas shrinkage following recurrent acute pancreatitis: an MRI study[J]. Eur Radiol,2019,29(7):3746-3756.
[9] Heberton G, Nassif M, Bierhals A, et al. Usefulness of psoas muscle area determined by computed tomography to predict mortality or prolonged length of hospital stay in patients undergoing left ventricular assist device implantation[J]. Am J Cardiol,2016,118(9):1363-1367.
[10] Carey E, Lai J, Wang C, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease[J]. Liver Transpl, 2017,23(5):625-633.
[11] Faron A, Pieper C C, Schmeel F C, et al. Fat-free muscle area measured by magnetic resonance imaging predicts overall survival of patients undergoing radioembolization of colorectal cancer liver metastases[J]. Eur Radiol,2019,29(9):4709-4717.
[12] Moorthi R, Avin K. Clinical relevance of sarcopenia in chronic kidney disease[J]. Curr Opin Nephrol Hypertens,2017,26(3):219-228.
[13] Carrara G, Pecorelli N, De Cobelli F, et al. Preoperative sarcopenia determinants in pancreatic cancer patients[J]. Clin Nutr, 2017,36(6):1649-1653.
[14] Joglekar S, Asghar A, Mott S L, et al. Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma[J]. J Surg Oncol, 2015,111(6):771-775.
[15] Onesti J, Wright G, Kenning S, et al. Sarcopenia and survival in patients undergoing pancreatic resection[J]. Pancreatology,2016,16(2):284-289.
[16] Bano G, Trevisan C, Carraro S, et al. Inflammation and sarcopenia: a systematic review and meta-analysis[J]. Maturitas, 2017,96: 10-15.
[17] Petrov M S. Skeletal muscle: a new piece in the pancreatitis puzzle[J]. United European Gastroenterol J, 2019,7(10):1283-1284.
[18] Guerra B, Santana A, Fuentes T, et al. Leptin receptors in human skeletal muscle[J]. J Appl Physiol, 2007, 102(5):1786-1792.
[19] Singh R G, Pendharkar S A, Gillies N A, et al. Associations between circulating levels of adipocytokines and abdominal adiposity in patients after acute pancreatitis[J]. Clin Exp Med,2017,17(4):477-487.
[20] Kim H, Kim M, Kojima N, et al. Exercise and nutritional supplementation on community-dwelling elderly Japanese women with sarcopenic obesity: a randomized controlled trial[J]. J Am Med Dir Assoc,2016, 17(11):1011-1019.
[21] Santoro A, Guidarelli G, Ostan R, et al. Gender-specific association of body composition with inflammatory and adiposerelated markers in healthy elderly Europeans from the NU-AGE study[J]. Eur Radiol, 2019,29(9):4968-4979.
[22] Manoy P, Anomasiri W, Yuktanandana P, et al. Elevated serum leptin levels are associated with low vitamin D, sarcopenic obesity, poor muscle strength, and physical performance in knee osteoarthritis[J]. Biomarkers, 2017,22(8):723-730.
[23] Sconfienza L M. Sarcopenia: ultrasound today, smartphones tomorrow[J] Eur Radiol,2019,29(1):1-2.
[24] Wolsk E, Mygind H, Grøndahl T, et al.Human skeletal muscle releases leptin in vivo[J]. Cytokine, 2012, 60(3):667-673.
[25] Sáinz N, Rodríguez A, Catalán V, et al. Leptin reduces the expression and increases the phosphorylation of the negative regulators of GLUT4 traffic TBC1D1 and TBC1D4 in muscle of ob/ob mice[J]. PLoS One, 2012,7(1):e29389.
PDF(1175 KB)
